A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
- Submitting institution
-
Queen Mary University of London
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 1678
- Type
- D - Journal article
- DOI
-
10.1056/NEJMoa1405044
- Title of journal
- New England Journal of Medicine
- Article number
- -
- First page
- 711
- Volume
- 372
- Issue
- 8
- ISSN
- 0028-4793
- Open access status
- Out of scope for open access requirements
- Month of publication
- February
- Year of publication
- 2014
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
26
- Research group(s)
-
D - Wolfson
- Citation count
- 686
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Between 2015 and 2017, a series of publications presented the results of a randomised international double-blind study of the use of the 9valent virus-like particle vaccine, Gardasil9 (NCT00543543 - the Broad Spectrum HPV Vaccine Study). Prof. Cuzick, as the only statistician appointed to the Study Scientific Advisory Committee, and as a co-author on the resulting publications, played a “major role in the design, regular review, and analysis of…and especially in the interpretation of the data”.
- Non-English
- No
- English abstract
- -
